AntriaBio Inc (OTCQB:ANTB)

Data as of Apr 15
 0.00 / 0.00%
Today’s Change
Today|||52-Week Range
Technology Services
Internet Software/Services

Company Description

AntriaBio, Inc. is engaged in the development and sale of novel therapeutic products for the diabetes market. Its products include AB 101 and AB 201. The AB 101 is administered by subcutaneous injection and targets patients with type 1 and type 2 diabetes who require basal insulin for the control of hyperglycaemia. The AB 201 supports the development of Glucagon-like peptide-1 (GLP), which helps control glucose levels. The company was founded on July 26, 2010 and is headquartered in Menlo Park, CA.

Contact Information

AntriaBio, Inc.
890 Santa Cruz Avenue
Menlo Park California 94025
P:(650) 241-9330
Investor Relations:



Individual stakeholders22.62%
Mutual fund holders--
Other institutional--

Top Executives

Nevan C. ElamPresident, Chief Executive Officer & Director
Sankaram MantripragadaChief Scientific Officer
Keith ChunDirector-Clinical Development
Jamie SpringHead-Investor Relations

To view my watchlist

Not a member yet?

Sign up now for a free account
Market indexes are shown in real time, except for the DJIA, which is delayed by two minutes. All times are ET. Disclaimer LIBOR Warning: Neither BBA Enterprises Limited, nor the BBA LIBOR Contributor Banks, nor Reuters, can be held liable for any irregularity or inaccuracy of BBA LIBOR. Disclaimer. Morningstar: © 2014 Morningstar, Inc. All Rights Reserved. Disclaimer The Dow Jones IndexesSM are proprietary to and distributed by Dow Jones & Company, Inc. and have been licensed for use. All content of the Dow Jones IndexesSM © 2014 is proprietary to Dow Jones & Company, Inc. Chicago Mercantile Association. The market data is the property of Chicago Mercantile Exchange Inc. and its licensors. All rights reserved. FactSet Research Systems Inc. 2014. All rights reserved. Most stock quote data provided by BATS.